Patents by Inventor Klaus Peter Hirth

Klaus Peter Hirth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
    Publication number: 20110059963
    Abstract: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
    Type: Application
    Filed: October 18, 2010
    Publication date: March 10, 2011
    Inventors: Prabha N. Ibrahim, Dean R. Artis, Ryan Bremer, Shumeye Mamo, Chao Zhang, Jiazhong Zhang, James Tsai, Klaus-Peter Hirth, Gideon Bollag, Wayne Spevak, Hanna Cho, Samuel J. Gillette, Shenghua Shi
  • Compounds and methods for kinase modulation, and indications therefor
    Patent number: 7872018
    Abstract: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
    Type: Grant
    Filed: December 20, 2007
    Date of Patent: January 18, 2011
    Assignee: Plexxikon, Inc.
    Inventors: Prabha N. Ibrahim, Ryan Bremer, Chao Zhang, Jiazhong Zhang, Klaus-Peter Hirth, Guoxian Wu, Hongyao Zhu
  • Compounds and methods for kinase modulation, and indications therefor
    Patent number: 7863288
    Abstract: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
    Type: Grant
    Filed: June 21, 2006
    Date of Patent: January 4, 2011
    Assignee: Plexxikon, Inc.
    Inventors: Prabha N. Ibrahim, Dean R. Artis, Ryan Bremer, Shumeye Mamo, Chao Zhang, Jiazhong Zhang, James Tsai, Klaus-Peter Hirth, Gideon Bollag, Wayne Spevak, Hanna Cho, Samuel J. Gillette, Shenghua Shi
  • COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
    Publication number: 20100256365
    Abstract: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
    Type: Application
    Filed: November 10, 2009
    Publication date: October 7, 2010
    Inventors: Prabha N. Ibrahim, Dean R. Artis, Ryan Bremer, Gaston Habets, Shumeye Mamo, Marika Nespi, Chao Zhang, Jiazhong Zhang, Yong-Liang Zhu, Rebecca Zuckerman, Brian West, Yoshisa Suzuki, James Tsai, Klaus-Peter Hirth, Gideon Bollag, Wayne Spevak, Hanna Cho, Samuel J. Gillette, Guoxian Wu, Hongyao Zhu, Shenghua Shi
  • COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
    Publication number: 20100249118
    Abstract: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
    Type: Application
    Filed: June 21, 2006
    Publication date: September 30, 2010
    Inventors: Prabha N. Ibrahim, Dean R. Artis, Ryan Bremer, Shumeye Mamo, Chao Zhang, Jiazhong Zhang, James Tsai, Klaus-Peter Hirth, Gideon Bollag, Wayne Spevak, Hanna Cho, Samuel J. Gillette, Shenghua Shi
  • COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
    Publication number: 20080221148
    Abstract: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
    Type: Application
    Filed: December 20, 2007
    Publication date: September 11, 2008
    Inventors: Prabha N. Ibrahim, Ryan Bremer, Chao Zhang, Jiazhong Zhang, Klaus-Peter Hirth, Guoxian Wu, Hongyao Zhu
  • Method and compositions for inhibiting cell proliferative disorders
    Patent number: 7217737
    Abstract: The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity HER2 or EGFR.
    Type: Grant
    Filed: June 25, 2003
    Date of Patent: May 15, 2007
    Assignees: Yissum Research and Development Company of the Hebrew University of Jerusalem, Sugen, Inc.
    Inventors: Hui Chen, Aviv Gazit, Alexander Levitzki, Klaus Peter Hirth, Elaina Mann, Peng Cho Tang, Laura K. Shawver, Jianming Tsai
  • Indolinone combinatorial libraries and related products and methods for the treatment of disease
    Patent number: 7202265
    Abstract: The present invention relates to organic molecules capable of modulating, regulating and/or inhibiting protein kinase signal transduction. Such compounds are useful for the treatment of diseases related to unregulated protein kinase signal transduction, including cell proliferative diseases such as cancer, atherosclerosis, arthritis and restenosis and metabolic diseases such as diabetes. The present invention features indolinone compounds that potently inhibit protein kinases and related products and methods. Inhibitors specific to the FLK protein kinase can be obtained by adding chemical substituents to the 3-[(indole-3-yl)methylene]-2-indolinone, in particular at the 1? position of the indole ring. Indolinone compounds that specifically inhibit the FLK and platelet derived growth factor protein kinases can harbor a tetrahydroindole or cyclopentano-b-pyrrol moiety.
    Type: Grant
    Filed: February 24, 2004
    Date of Patent: April 10, 2007
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Connie Li Sun, Gerald McMahon, Klaus Peter Hirth, Laura Kay Shawver
  • 4-substituted 7-AZA-indolin-2-ones and their use as protein kinase inhibitors
    Patent number: 6908930
    Abstract: This invention relates to 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors. Particular 4-substituted 7-aza-indolin-2-ones disclosed herein are of Formula 1 and pharmaceutically acceptable salts, solvates, clathrates, and prodrugs thereof, wherein R1, R2, R3, R4, X, Y, and Z are defined herein. The invention further relates to pharmaceutical compositions and dosage forms comprising compounds of Formula 1 and to methods of their use for the treatment and/or prevention of diseases such as, but not limited to, cancer.
    Type: Grant
    Filed: July 21, 2003
    Date of Patent: June 21, 2005
    Assignee: Sugen, Inc.
    Inventors: Congxin Liang, Li Sun, Chung Chen Wei, Peng Cho Tang, Gerald McMahon, Klaus Peter Hirth, Jingrong Cui
  • Indolinone combinatorial libraries and related products and methods for the treatment of disease
    Patent number: 6906093
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: July 3, 2001
    Date of Patent: June 14, 2005
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon, Klaus Peter Hirth, Laura Kay Shawver
  • Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
    Patent number: 6846839
    Abstract: The present invention relates to methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis. More specifically, this invention relates to methods for treating diseases and disorders, such as rheumatoid arthritis, endometriosis, ocular neovascularization, solid tumor growth and metastases, and excessive scarring during wound healing, with indolinone compounds.
    Type: Grant
    Filed: June 16, 1999
    Date of Patent: January 25, 2005
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Laura Kay Shawver, Klaus Peter Hirth, Annie Fong
  • Method and compositions for inhibiting cell proliferative disorders
    Publication number: 20040242684
    Abstract: The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers charcterized by over-activity or inappropriate activity HER2 or EGFR.
    Type: Application
    Filed: June 25, 2003
    Publication date: December 2, 2004
    Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem, SUGEN, Inc.
    Inventors: Hui Chen, Aviv Gazit, Alexander Levitzki, Klaus Peter Hirth, Elaina Mann, Laura K. Shawver, Jianming Tsai, Peng Cho Tang
  • Methods for the design of molecular scaffolds and ligands
    Publication number: 20040171062
    Abstract: The present invention provides methods of designing ligands that specifically bind to target molecules by testing a set of distinct compounds to identify compound that bind to member of a molecular family of interest. Those compounds that show binding activity can be used as a starting point for ligand design. Unlike previous methods, even compounds that bind with only low affinity are of interest and can be used. Common chemical structures of binding molecules including low affinity binding molecules are identified, thereby providing molecular scaffolds. Co-crystals of the protein and the molecular scaffolds can be formed and analyzed by X-ray crystallography to determine the orientation of the scaffold compounds at the binding site of the molecule.
    Type: Application
    Filed: February 28, 2003
    Publication date: September 2, 2004
    Applicant: Plexxikon, Inc.
    Inventors: Klaus-Peter Hirth, Michael Vance Milburn
  • Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders
    Publication number: 20040102489
    Abstract: The present invention relates to novel heteroaryl-carboxamides which modulate the activity of protein tyrosine kinases and therefore are expected to be useful in the treatment of abnormal protein tyrosine kinase activity driven disorders including cancer.
    Type: Application
    Filed: November 17, 2003
    Publication date: May 27, 2004
    Applicant: Sugen, Inc.
    Inventors: Gerald McMahon, Peng Cho Tang, Laura Kay Shawver, Klaus Peter Hirth
  • 4-Substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
    Publication number: 20040053924
    Abstract: This invention relates to 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors.
    Type: Application
    Filed: July 21, 2003
    Publication date: March 18, 2004
    Applicant: SUGEN, INC.
    Inventors: Congxin Liang, Li Sun, Chung Chen Wei, Peng Cho Tang, Gerald McMahon, Klaus Peter Hirth, Jingrong Cui
  • 3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
    Patent number: 6696448
    Abstract: The present invention relates to novel 3-(piperazinyl-benylidenyl)-2-indolinone compounds and derivatives and physiologically acceptable salts thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: July 24, 2002
    Date of Patent: February 24, 2004
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon, Laura Kay Shawver, Klaus Peter Hirth
  • METHOD OF DETERMINING AN EFFICACIOUS DOSE OF A DRUG
    Publication number: 20030219380
    Abstract: The present invention relates to a method of determining an efficacious dose of a drug administered to a subject for the purpose of modulating angiogenesis, including conditions manifested by cell proliferation, cell differentiation, or cell survival. The method comprises the step of monitoring a marker related to angiogenesis. The drug used in the present invention is an indolinone compound. The invention also features a kit for determining the efficacious dose of the drug.
    Type: Application
    Filed: November 4, 1998
    Publication date: November 27, 2003
    Inventors: ANNIE FONG, KLAUS PETER HIRTH
  • Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders
    Patent number: 6649635
    Abstract: The present invention relates to novel heteroaryl-carboxamides which modulate the activity of protein tyrosine kinases and therefore are expected to be useful in the treatment of abnormal protein tyrosine kinase activity driven disorders including cancer.
    Type: Grant
    Filed: September 7, 2001
    Date of Patent: November 18, 2003
    Assignee: Sugen, Inc.
    Inventors: Gerald McMahon, Peng Cho Tang, Laura Kay Shawver, Klaus Peter Hirth
  • 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
    Patent number: 6610688
    Abstract: This invention relates to 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors. Particular 4-substituted 7-aza-indolin-2-ones disclosed herein are of Formula 1 and pharmaceutically acceptable salts, solvates, clathrates, and prodrugs thereof, wherein R1, R2, R3, R4, X, Y, and Z are defined herein. The invention further relates to pharmaceutical compositions and dosage forms comprising compounds of Formula 1 and to methods of their use for the treatment and/or prevention of diseases such as, but not limited to, cancer.
    Type: Grant
    Filed: December 21, 2000
    Date of Patent: August 26, 2003
    Assignee: Sugen, Inc.
    Inventors: Congxin Liang, Li Sun, Chung Chen Wei, Peng Cho Tang, Gerald McMahon, Klaus Peter Hirth, Jingrong Cui
  • Methods and compositions for inhibiting cell proliferative disorders
    Patent number: 6596878
    Abstract: The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity HER2 or EGFR.
    Type: Grant
    Filed: September 18, 2001
    Date of Patent: July 22, 2003
    Assignees: Yissum Research & Development Company of the Hebrew University, Sugen, Inc.
    Inventors: Hui Chen, Aviv Gazit, Alexander Levitzki, Klaus Peter Hirth, Elaina Mann, Laura K. Shawver, Jianming Tsai, Peng Cho Tang